For decades, clinirians at'd i'esearchers did not distinguish between bipolar and unipolar depression. The safety and efficacy of antidepressants for the treatment of unipolar depression were studied, and the data were applied to the treatment of bipolar depression without validation. As evidence has accumulated that antidepressants may adverse ly affect the course of bipolar illness, more research has been focused on that problem. Current evidence suggests that although antidepressants are clearly effective in the acute treatment of type I and type II bipolar depression, they are also associated with a variety of adverse outcomes. They maf induce a switch to mania or hypomania at a rate two or three times the spontaneous rate. Long-term use may destabilize the illness, leading to an increase in the number of both manic and depressed episodes; induce rapid cycling (at least four episodes a year); and increase the likelihood of a mixed state. Antidepressants should be used with caution in the treatment of bipolar depression. (Psychiatric Services 53 :5 lJ0-584, ZOOZ) ipolar disorder. or manic-depression. is chlllcnging to manage. The primary goal of pharmacotheraJry is to prevent recurrence of mania and depression. However, although mood stabilizers are generally effective in treating and preventing mania (1-5), their efficacy in treating depression is suboptimal (1, [6] [7] [8] [9] . This is unfortunate, because people with bipolar disorler seern to have greater ploblems uith depression than with marria.
Cross-sectionllly. outlatients with bipolar disorder are significantly more likely to be clepresse d than those with mania or hl,pomania (29.8 percent comparecl rvith 7.9 percent) (10) and less likely to respond to treatment with either a mood stabilizer or an antidepressant (10, 11) . Persons with bipollr clisorder spend much more time deprcssed than in a manic or hypomanic state (49 percent compared with l2 percent), as demonstrated in a study of 27 patients with type I bipolar disorder, l1 patients with type II bipolar disorder, and six patients with bipolar disorder not otherwise specified (12) .
Frequently, persons with bipolar disorder initially receive a diagnosis of unipolar depression (13) along with a prescription for an antidepressant (12, 14) . Although antidepressants appear to be effective. they are now also believed to be not infrequently associated with adverse consequences for the course of bipolar illness. Thus it is important to carefully diagnose mood disturbances, to closely monitor treatment, and to keep informed about the most recent data. In this article we review the most recent data on the use of antidepressants for bipolar disorders.
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Diagnosis of bipolar illness
For the purposes of diagnosis, the key feature of bipolur illness is a manic or hypomanic episode. When an episode is actually witnessed by a clinician, the diagnosis is usually straightforward. In a community sample of 1,709 adolescents with bipolar disorder, Lewinsohn and colleagues (15) found that 61 percent presented with an initial episode of depression. Such an episode can often result in a diagnosis of unipolar depression. Thus when Geller and associates (16) conducted a ten-year follow-up study of 72 prepubertal children with major depression, they found that 33.3 percent met criteria for type I bipolar disorder and 15.3 percent met criteria for type II bipolar disorder (16).
The rate of misdiagnosis is also high among adults. In a study in which the Structured Clinical Interview for DSM-IV (SCID) was administered to patients who presented with a major depressive episode, more than half (55 percent) were found to have bipo lar disorder (17) . In a survey of 400 members of the National Depressive and Manic-Depressive Association, 60 percent of the patients who identified their illness as bipolar disorder reported that their initial diagnosis was depression (11).
Ghaemi and associates (12, 18 ) used a modified version of the SCID to provide prospective diagnoses for consecutively referred patients with bipolar illness. Forly percent in one sample (18) and more than half (54 percent) in another (12) had previ. ously received misdiagnoses. The mean duration between the first contact with the mental health system and the correct diagnosis among patients with type I bipolar disorder was 5.9 years. The mean delal for type II illness was much longcr at I 1.6 1'cars. These delays are significantly iongcr than the lag of 3.3 1'ears in the diagnosis of unipolar depressron (12) .
Even when thc initial diagnosis is made carcfnlly and sl,stcr.natically. the rate of missecl bipolar illness can be high. In an 1 1-year-follow-up study of 559 patients with unipolar depression initially diagnosed with the SCID, 3.9 percent were subsequently found to have t.v-pc I bipolar' disorder and 8.6 percent to have typc II bipolar disorder ( l9)
When the initial presentation is depression ancl there is no clear history of mania or h1'pomania. certain clues can raise the ir.rdcx of susprcion. One of the most important clucs for children is a family history of manic-depression (20) . In addition. a ps1'chotic illness, prepubertal or postpartum onset ofdepression, uncl a severe vegetative depression are r-nL)re lrequently associated with subsequcnt development of bipoiar illness (16.20). Akiskal and collcagues (21) found that the mean duration betu'een the index depressive episodc and the appearance of the filst manic or hypomanic episode among adults was 6.4 years. They observed prcdisposing characteristics iu.nong theil subjccts similar to those noted in thc other studies, particul:rrly a famill' history of bipolar disorder, early onset (before the age of 25 yeals.t. postparturn onset, and a severc vegetative depression (21) . Amr,r'g both irdults antl children. antidepr':ssant-indrrced mania or hypomanili rr,as a good predictor of the preserrce or subsequent development of bipolar disorder (20. 21), although DSM-fV defines this type of disordcr as substunce-induced mania (22). If any threc o1 the predisposing charactcri;tics \\,ere present, the likelihood rn;:; 98 pcrceirt that the ultimate diagncisis ri'oulcl be manic depression (2 l.). lcagues (23, 24) found that the monoamine oxidase inhibitor (MAOI) tranylcypromine was superior to placebo in the treatment of 29 patients with type I or type II bipolar depression and superior to imipramine among 56 patients with bipolar depression. In a study by Thase and associates (27), nine ofthe l2 patients who did not respond to imipramine responded to tranylcypromine, whereas only one of the four rvho did not respond to tranylcypromine responded to imipramine.
Imipramine was equivalent to paroxetine in the treatment of 60 patients rvith bipolar depression who were already taking either lithium alone or lithium plus another mood stabiliz.er and who had either of the two antidepr-essants (19 subjects in each treatment group) or placebo (22 subjects) added to their regimen (32) . However, among patients for whom lithium was used aggressivelyserum concentrations above .8 mEq/L -the antidepressants did not provide additional efficacy in treating the depression (32) .
On the other hand. fluoxetine was found to be more effective than imipramine in a small double-blind, placebo-controlled comparison of patients with bipolar depression who ,^ t:"r" also taking lithium (25). Either active medication was superior to placebo, and fluoxetine was associated with a highcr response rate than imipramine (86 percent and 57 percent, respectively) (25). Desipramine and bupropion were found to be equivalent in a double-blind study of l5 patients with bipolar depression who received mood stabilizers as maintenance therapy (33) . About 7l percent of the patients who received desipramine and 63 percent of those who received bupropion experienced improvement of more than 50 percent (33) .
In an open-label study, the first author administered methylphenidate for 12 weeks to 14 patients with mild to moderate bipolar depression-ten with type I bipolar disorder, two with type II bipolar disorder, and two with secondary mania-who were also taking mood stabilizers (31) . A last-observation-carried-forward (LOCF) intention-to-treat analysis showed a significant improvement in depressive symptoms as indicated by mean scores on the 2l-item Hamilton Depression Rating Scale (HDRS) (from 16.9 at baseline to 9.8 on the LOCF). (Possible scores on the HDRS range from 0 to 62, with a score of 15 indicating depression and higher scores representing more severe depression.) The response by the end of the first week was an excellent predictor of response at the end of the study.
Placebo-controlled studies have not been conducted among children with bipolar depression. Biederman and colleagues (30) reviewed tbe charts of 59 youths with a mean age of 10.8 years (range, 3.5 to l1 years), 83 percent of whom were male, who had DSM-III-R diagnoses of bipolar disorder and who were studied for up to four years. They found that selective serotonin reuptake inhibitors (SSRIs) were significantly associated with improvement in depressive symptoms between visits. Antidepressants also may be effective for type II bipolar depression. Amsterdam and colleagues (29) retrospectively examined participants in a long-term study of fluoxetine for DSM-III-R major depression in which hypomania (type II bipolar disorder) was not exclusionary. They identified 89 patients with type II bipolar disorder among 839 patients studied. They compared 5Rl these patients lvith 89 age-and sexmatched paticnts rvith r-rnipolar depression and 66i unmatched patients with unipolar depression. No differences were found between groups in the efficacy offluoxetine for the treatment or prevention of depression.
The same resear.chers also studied monotherapy',vitl.r venlafaxine 225 mg a day among 17 paticnts rvith type II bipolar cleprc-.sron. Redr-rctions in mean scores on thc t{l)RS (fiom 22 to 9) and thc Nlorrtgolncrl' Asberg Depression Rating Scalc (NIADRS) (from 22 to 9; u ere significant and were equivalenf to those seen among 26 patients with unipolar disorder over the six wceks ol the stud1, (28). (Possible scores or the: MADRS range from 0 to 60. with higher scores indicating more \i.r.,'ere <iepression.)
The prophvlactic eff icacy of antidepressants has not beerr as w'ell studied.
Quitkin and associrtes (J,1) conducted a 30-month dor,bl;-b1ind study of the efficacy of imipliinrinc compared wlth placebo added to lithium in thc prevention of depre,,si,'c relaDse among 7-5 patients with tlpe I b,polar disorder and found that imiprur-ninc was ineffective in prcventing bipolar dcplcssion. Three (8 percenl of 37 paticnts who received imiprln'in,: and tbur (10.-5 percent) of 38 I'ho rccei.,ed placebo experienced deplc: srve t'elrltsc (-j4).
Antideprcssanls lur(f Inlrnia Antidepressanl rrr 'Jie.it,on\ apDcilr t() induce mania or r upid cvcling-that is, at least four epist--dcs a vear-among some patients ,vitl-, bipollr disorder (12, (35) (36) (37) . The absolutc rate of manic induction rs ctrrite varied among studies. Howei'.:r', r','lren sp,ontaneous switch rates r,l i'rr] ti'ro prescnted in the studies, thc ilr.te of ir.rtidcprcssant-induced m;ria ioas consisfently two or three tirre. tirc: sp.rntaneous rate (29,34,36-10 i.
In type I bi;,11r1r-,.lisorder. antidepressant-indr.rced rnlnia is generally mixed or has a ';isnificalll irritabie mood component, and it rcrsolves relatively quickll' r',hcn ihc a,l:id€pressant is discontinued l3i,r. Pcrsorrs rvith type II bipolar disorrlcl in.iy sLic,r.l' a similar pattern. Patient: r.'. ith cl clothymia may switch to t1'pe li ,line::; u,hen treated with antideprcssr.lris (.1 .).
One of the eart,cst r,rcr)rtS of anti5Rt depressant-induced mania was presented by Wehr and Goodwin (35) . In the study by Nemeroff and colleagues (12) in uhich imiprumine. paroxetine.
and placebo added to lithium with or without another mood stabilizer were compured. a switch to mania occurred more frequently among patients who had serum lithium concentrations below .8 mEq/L. At these concentrations, I I percent of the patients who received imipramine and 5 percent of those who were treated rvith mood stabilizers alone (spontaneous rate) became manic or hypomanic. At lithium concentrations above .8 mEq/L, none of the patients who received mood stabilizers alone switched, compared with 8 percent of the patients who were treated with imipramine. In the study by Wehr and Goodwin, none of the 33 patients rvho received paroxetine experienced a switch to mania or hypomania (35) . Similar results were reported in the 30-month relapse study by Quitkin and colleagues (34) . The risk of manic relapse was twice as high for pltients treirted with imipramine (nine of 37 patients, or 24 percent) as for those who received placebo (four of 38 patients, or 10.5 percent) percent), although this effect was not significant.
However, manic induction is not exclusively related to tricyclic antidepressants. Altshuler and colleagues (37) retrospectively reviewed the life charts of 51 patients with treatmentrefractory bipolar illness. More than a third of the patients (35 percent) had antidepressant-associated manic episodes. Patients with antidepressantinduced mania had a greater risk of rapid cycling than those who did not (46 percent and 14 percent, respectively). Ghaemi and associates (12) reviewed the charts of 27 patients with type I bipolar disorder, l1 patients with type II bipolar disorder, and 16 patients with bipolar disorder not otherwise specified whose diagnoses had been made on the basis of a modified SCID. A total of 42 patients had received antidepressant treatment at some point, but sufficient data for analyses were available for oniy 38 patients. Fifty-five percent had experienced an antidepressant-related mania or hvoomania. In both studies. the patients had received either SSRI or non-SSRI antidepressants.
Longer duration of antidepressant treatment may increase the risk of a manic switch. The Stanley Foundation Bipolar Network is currently conducting a comparative study of antidepressants for breakthrough depression among patients with bipolar disorder (42, 43) . During a ten-week acute phase, 18.2 percent of 1,035 patients experienced either mania or hypomania (43) . At a one-year followup, 16.4 percent had experienced a switch to mania and 19.2 oercent to hypomania (43) .
In a double-blind comparative study, desipramine induced mania or hypomania during the first eight weeks of treatment among 30 percent of patients, compared with only 1l percent of patients treated with bupropion-a significant difference (33) .
In a study of 49 consecutively admitted patients with antidepressantinduced mania and 49 matched control patients with spontaneous mania. the antidepressant-induced mania was consistently less severe than the spontaneous mania (36) . Overall severity of mania at admission was lower among the patients who received bupropion or an MAOI than among those who received a tricyclic agent or fluoxetine (36) .
Kupfer and associates (40) examined the incidence of imipramine-induced mania among 33 patients with type II bipolar disorder and 197 patients with unipolar depression. All the patients received imipramine at a target dosage of 200 mg a day as well as interpersonal psychotherapy for 40 weeks. Six patients developed hypo mania, and none developed mania. Of the six, four developed hypomania after more than 20 weeks of treatment, and the other two after 16 weeks or less (40) .
Antidepressant-induced mania may also occur among children. Biederman and colleagues (30) found that SSRIs were associated with a significantly greater probability of manic symptoms than no antidepressant treatment. Cicero and associates (44) have noted that children who were treated with stimulants or antidepressants were given a bipolar diagnosis two years earlier than children who had not receivcd thosc rncdications, although the dificrencc wns not significant. In a sirt.rrl:,r. str-rdy. L)clBcllo and colleagues (451 ii.unci rha{ the me'rn time to onsct oi brpolal disorder r.vas more than threc y,ars lcss Irrr 2l children rvho har-1 reccilccl :tirnulants than for 13 chilore r.r ri;ro h,rcl not (10.7 years and 13.9 ic,ris. rcs[)c!ti\clv).
Not all studic', -tuvr-: :lrou'n such associations betr'. ce ir antid jpressiints and mania. Lcir is ancl \rVinokur (46) retrospectivclv .-:rarnined thc cha|ts of 87 patients rvi.r(, irt uCmir sion, rvere neither mirnic lror rcuerring antidepressants. Thc :witch rates r. review of 109 patients with bipolar disorder who were experiencing rapid c1'cling, Kukopulos and colleagues (38) found that among 80 patients i73.4 percent) the onset of rapid cycling was associated with antidepressant treatment; for the patients who continued to receive antidepressants, rapid cycling continued through euthymic periods in the case of 17 patients, persisted for at least a year in the case of 33 patients, for two years in the case of 14 patients, and for a longer period in the case of five patients (38) . The types of antidepressunts used were not specified. When Altshuler and colleagues (37) retrospectively reviewed the life charts of 5l patients with treatmentrefractory bipolar illness, they found that 26 percent experienced antidepressant-associated cycle acceleration. The risk of cycle acceleration uns significantly higher for the 35 peruent ofpatients who had previously experienced an antidepressant-induced mania than for those who had not (46 percent and 14 percent, respectively). Younger age at first treatment also predicted cycle acceleration (37) . No specific association with antidepressant class was found.
In the study by Ghaemi and collcrgues (12) ,23 percent of the 54 patients with bipolar disorder experienced cycle acceleration associated ivith antidepressant treatment. Most ofthese patients had received SSRIs. Interestingly, although the mean nurnbc| of episodes per yeur increased from 3.9 to 9.8, the episodes ri'ere sufficiently brief that the absolute duration of illness dropped from 60 percent to 45 percent.
Rapid cycling faded quickly among 29 percent of the 5l patients studied b1' Wehr and colleagues (47) . Similarly, for eight of nine patients studied by Altshuler and colleagues (37) , rapid cycling stopped rvithin two months after antidepressant treatment was ended. One patient experienced cycling for five months before stabilizing after antidepressant treatment was discontinued (37) .
These reports suggest that rapid cycling of manic and depressive episodes can both be induced by antidepressants and fade after discontinu-*,, ":tn" of antidepressants. The duration of antidepressant treatment before the onset of complications is variable, but rapid cycling appears to be associated with longer treatment periods and with treatment through euthymic periods. Similarly, recovery time after discontinuation of the drug may mirror the time required for episode induction, so that in some cases rapid cycling may resolve months after the patient has stopped taking antidepressants. Both SSRIs and tricyclic antidepressants have been implicated, although the relative risk is not clear. Data on bupropion are lacking.
Conclusions
Although antidepressants appear to be effective in the treatment of acute bipolar depression, their use is not without risk. Patients with bipolar disorder who are treated with antidepressants may have an elevated risk of mania, cycle acceleration, or induction of a chronic irritable dysphoric state. There is preliminary evidence that specific risk factors may be assc ciated with these complications, no tably long-term use of an antidepressant or administration of the drug during euthymic periods. Previous antidepressant-associated mania appears to predict subsequent rapid cycling. In general, tricyclic antidepressants are the most notorious, while SSRIs and bupropion appear to be safer. However, all antidepressant agents have been associated with these undesirable outcomes. It has been suggested that stimulants may be safer in short-term treatment of bipolar depression, but this needs to be investigated further.
A clinician confronted with a patient who has bipolar depression should first try treatment with a mood stabilizer. If an antidepressant is required, brief treatment----one to six monthswith subsequent tapering is desirable. Occasionally, chronic treatment will be needed. but this should not be the norm. Treatment of chronic conditions, such as an anxiety disturbance, is more problematic. Use of an alternative agent, such as gabapentin or an atypical antipsychotic, may be appro priate. Antidepressants clearly have a role in reducing the suffering of persons with bipolar depression but must be used judiciously and cautiously. t) 5Rl
